A phase 2 study on efficacy, safety and intratumoral pharmacokinetics of oral selinexor (KPT-330) in patients with recurrent glioblastoma (GBM).

被引：1
|
作者：
Mau-Sorensen, Morten
Plotkin, Scott Randall
Wen, Patrick Y.
Kung, Andrew L.
Lassen, Ulrik Niels
Saint-Martin, Jean-Richard
Wright, Greg
Chudnovsky, Aleksander
Ellis, Joel
Friedlander, Sharon
van Eijk, Bert
Shacham, Sharon
Kauffman, Michael G.
Lassman, Andrew B.
机构：
[1] Rigshospitalet, Copenhagen, Denmark
[2] Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA
[3] Dana Farber Canc Inst, Boston, MA 02115 USA
[4] Columbia Univ, Med Ctr, New York, NY USA
[5] Herbert Irving Comprehens Canc Ctr, New York, NY USA
[6] Karyopharm Therapeut Inc, Newton, MA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 15期
关键词：
D O I：
10.1200/JCO.2016.34.15_suppl.2077
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2077
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Phase 2 study to evaluate the clinical efficacy and safety of MEDI4736 in patients with glioblastoma (GBM)
    Reardon, David A.
    Dietrich, Jorg
    Kaley, Thomas
    Gan, Hui
    Dunn, Gavin P.
    Cloughesy, Timothy
    Lim, Michael
    Clarke, Jennifer
    Park, Andrew
    Pang, Linda
    Lai, Domenic W.
    Karakunnel, Joyson
    Robbins, Paul
    Narwal, Rajesh
    Venhaus, Ralph
    CANCER IMMUNOLOGY RESEARCH, 2016, 4 (01)
  • [22] Phase 2 study to evaluate the clinical efficacy and safety of MEDI4736 (durvalumab) in patients with glioblastoma (GBM).
    Reardon, David A.
    Kaley, Thomas Joseph
    Dietrich, Jorg
    Lim, Michael
    Dunn, Gavin P.
    Gan, Hui Kong
    Cloughesy, Timothy Francis
    Clarke, Jennifer Leigh
    Park, Andrew J.
    Macri, Mary J.
    Ryan, Aileen
    Ricciardi, Toni
    Reddy, Vijay
    Venhaus, Ralph Rudolph
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [23] MULTI-CENTER, PHASE 2 STUDY EVALUATING THE PHARMACOKINETICS, SAFETY AND PRELIMINARY EFFICACY OF PAXALISIB IN NEWLY DIAGNOSED ADULT PATIENTS WITH UNMETHYLATED GLIOBLASTOMA (GBM)
    Wen, Patrick Y.
    de Groot, John
    Battiste, James
    Goldlust, Samuel
    Damek, Denise
    Ellingson, Benjamin
    Garner, James
    Friend, John
    Simpson, Jeremy
    Olivero, Alan
    Cloughesy, Timothy
    NEURO-ONCOLOGY, 2022, 24 : 76 - 77
  • [24] ANTI-TUMOR ACTIVITY OF SELINEXOR (KPT-330), AN ORAL SELECTIVE INHIBITOR OF NUCLEAR EXPORT (SINE), ± DEXAMETHASONE IN MULTIPLE MYELOMA PRECLINICAL MODELS & TRANSLATION IN PATIENTS WITH MULTIPLE MYELOMA
    Chen, C.
    Gutierrez, M.
    Brown, P.
    Gabrail, N.
    Baz, R.
    Reece, D.
    Flinn, I.
    Trudel, S.
    Siegel, D.
    Mau-Sorensen, M.
    Kuruvilla, J.
    Carlson, R.
    McCauley, D.
    Shacham, E.
    Saint-Martin, J. R.
    McCartney, J.
    Marshall, T.
    Landesman, Y.
    Friedlander, S.
    Pond, G.
    Rebello, S.
    Rashal, T.
    Shacham, S.
    Kauffman, M.
    Mirza, M.
    HAEMATOLOGICA, 2014, 99 : 359 - 359
  • [25] PHASE 2 STUDY OF SYM004 FOR ADULT PATIENTS WITH RECURRENT GLIOBLASTOMA (GBM)
    Desjardins, Annick
    Randazzo, Dina
    Peters, Katherine B.
    Johnson, Margaret O.
    Massey, Woody
    Herndon, James E., II
    McSherry, Frances
    Lipp, Eric S.
    Nadler, Paul
    Horak, Ivan D.
    Friedman, Henry S.
    NEURO-ONCOLOGY, 2017, 19 : 14 - 14
  • [26] Phase II Results of Ara-C and Idarubicin in Combination with the Selective Inhibitor of Nuclear Export (SINE) Compound Selinexor (KPT-330) in Patients with Relapsed or Refractory AML
    Fiedler, Walter
    Heuser, Michael
    Chromik, Joerg
    Thol, Felicitas
    Bokemeyer, Carsten
    Theile, Susann
    Lebkuechner, Isabell
    Kranich, Anne L.
    BLOOD, 2016, 128 (22)
  • [27] SAFETY AND EFFICACY OF BEVACIZUMAB AND ERLOTINIB FOR RECURRENT GLIOBLASTOMA PATIENTS IN A PHASE II STUDY
    Sathornsumetee, Sith
    Desjardins, Annick
    Vredenburgh, James
    Rich, Jeremy
    Gururangan, Sridharan
    Friedman, Allan
    Friedman, Henry
    Reardon, David
    NEURO-ONCOLOGY, 2008, 10 (05) : 827 - 827
  • [28] Phase I study of the intratumoral administration of an oncolytic polio/rhinovirus recombinant (PVSRIPO) in recurrent glioblastoma (GBM)
    Desjardins, Annick
    Sampson, John Howard
    Peters, Katherine B.
    Ranjan, Tulika
    Vlahovic, Gordana
    Watts, Jason
    Threatt, Stevie
    Herndon, James Emmett
    Boulton, Susan
    Lally-Goss, Denise
    McSherry, Frances
    Friedman, Allan H.
    Friedman, Henry S.
    Bigner, Darell D.
    Gromeier, Matthias
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [29] PHASE 2 STUDY TO EVALUATE THE CLINICAL EFFICACY AND SAFETY OF MEDI4736 (DURVALUMAB [DUR]) IN PATIENTS WITH BEVACIZUMAB (BEV)-REFRACTORY RECURRENT GLIOBLASTOMA (GBM)
    Reardon, David
    Kaley, Thomas
    Dietrich, Jorg
    Clarke, Jennifer L.
    Dunn, Gavin P.
    Lim, Michael
    Cloughesy, Timothy
    Gan, Hui K.
    Park, Andrew
    Schwarzenberger, Paul
    Ricciardi, Toni
    Macri, Mary
    Ryan, Aileen
    Venhaus, Ralph
    NEURO-ONCOLOGY, 2017, 19 : 28 - 28
  • [30] A first-in-class, first-in-human phase I trial of KPT-330 (selinexor), a selective inhibitor of unclear export (SINE) in patients (pis) with advanced solid tumors
    Mau-Soerensen, Morten
    Razak, Albiruni R. A.
    Shields, Anthony Frank
    Gabrall, Nashat Y.
    Gereeltano, John F.
    Shacham, Sharon
    Lassen, Ulrlk Niels
    Rashal, Taml
    Cooksoy, Jennifer
    Landosman, Yosof
    Pond, Gregory
    Oza, Amit M.
    Kauffman, Michael
    Siu, Lillian L.
    Bedard, Philippe L.
    Mahaseth, Hemchandra
    Mlrza, Mansoor Raza
    Mahipal, Arnit
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
12345